Less active enantiomer of H3 agonist R-(-)-α-methylhistamine (Cat. No. 0569); 120-fold less potent than R-(-) at H3.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 100 mM in water|
Preparing Stock Solutions
The following data is based on the product molecular weight 287. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.48 mL||17.42 mL||34.84 mL|
|5 mM||0.7 mL||3.48 mL||6.97 mL|
|10 mM||0.35 mL||1.74 mL||3.48 mL|
|50 mM||0.07 mL||0.35 mL||0.7 mL|
References are publications that support the products' biological activity.
Hill (1990) Distribution, properties and functional characteristics of three classes of histamine receptor. Pharmacol.Rev. 42 45 PMID: 2164693
If you know of a relevant reference for (S)-(+)-α-Methylhistamine dihydrobromide, please let us know.
View Related Products by Product Action
Keywords: (S)-(+)-alpha-Methylhistamine dihydrobromide, supplier, H3, agonists, Receptors, Histamine, histaminergic, (S)-(+)-alpha-Methylhistamine, dihydrobromide, Histamine, H3, Receptors, Histamine, H3, Receptors, Tocris Bioscience
Citations for (S)-(+)-α-Methylhistamine dihydrobromide
Citations are publications that use Tocris products.
Currently there are no citations for (S)-(+)-α-Methylhistamine dihydrobromide. Do you know of a great paper that uses (S)-(+)-α-Methylhistamine dihydrobromide from Tocris? If so please let us know.
(S)-(+)-alpha-Methylhistamine dihydrobromide Reviews
Average Rating:(Based on 0 Reviews)
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.